API Docs
All documentation Fundamental API Live (Delayed) API EOD Historical API Intraday API Real-Time (Websockets) API Financial News API Delisted Data API
Solutions
New & Popular APIs
Show all APIs Fundamental Data APIs Indices Historical Constituents API 40 000 Stock Market Logos API Forex Data APIs
Other products
Google Sheets Add-on Excel Add-on Coding Libraries (Python, R, etc) Wordpress Add-on
API Marketplace
Community
Academy 134 articles Forum Github 13 repos
Pricing
Overview Fundamentals API Earnings EOD API Sample Code Pricing
Register now
Free trial

No credit cards required

Get free API key
  1. Supported exchanges /
  2. PINK /
  3. PXMD.PINK

PaxMedica, Inc. Common Stock (PXMD PINK) stock market data APIs

$0.0962 -0(-0%) as of September 6, 2024
Price chart is built with Anychart

PaxMedica, Inc., a clinical stage biopharmaceutical company, focuses on the development of anti-purinergic drug therapies for the treatment of disorders with intractable neurologic symptoms. Its lead product candidate is PAX-101 that is in Phase 3 clinical trials, an intravenous formulation of suramin for the treatment of autism spectrum disorder, myalgic encephalomyelitis/chronic fatigue syndrome, long COVID-19 syndrome, fragile X syndrome, human African trypanosomiasis (HAT), and fragile X-associated tremor/ataxia syndrome. The company is developing PAX-102, an intranasal formulation of suramin for neurologic indications, as well as other new chemical entities that are targeted and selective antagonists of purine receptor subtypes; and PAX-HAT-301 for the treatment of HAT. It has a research collaboration agreement with PolarMar Health for Phase II clinical trial in austism spectrum disorder for emodin, which retains the rights for PolarMar to develop and commercialize any non-prescription supplement form of the product, and for PaxMedica, Inc. to retain exclusive rights to develop and commercialize a highly purified form of emodin. The company was formerly known as Purinix Pharmaceuticals LLC and changed its name to PaxMedica, Inc. in April 2020. PaxMedica, Inc. was incorporated in 2018 and is based in Tarrytown, New York.

PaxMedica, Inc. Common Stock Financial Data Overview

0.0987
0.0962
-
0.0987
0.08
0.08-6.426
770 K
0.0015
7 780 K
0
-0.5
-0.515
Our easy-to-use no-coding solutions help you get the data effortlessly:
Excel Financial Add-In Google Sheets Financial Add-In Python
APIs SDK Windows Downloader

No long-term obligations. The minimum period is one month only. No wait. You get an API key with instructions in a few seconds right after subscription.

General: {
Code: 'PXMD',
Type: 'Common Stock',
Name: 'PaxMedica, Inc. Common Stock',
Exchange: 'PINK',
CurrencyCode: 'USD',
CurrencyName: 'US Dollar',
CurrencySymbol: '$',
CountryName: 'USA',
CountryISO: 'US',
OpenFigi: 'BBG00VVV2NQ7',
ISIN: NULL,
CUSIP: NULL,
CIK: '0001811623',
EmployerIdNumber: NULL,
FiscalYearEnd: 'December',
IPODate: '2022-08-26',
InternationalDomestic: NULL,
Sector: 'Healthcare',
Industry: 'Biotechnology',
HomeCategory: NULL,
IsDelisted: false,
}

PaxMedica, Inc. Common Stock Fundamental Data is available in our Financial Data APIs

  • Net Revenue 0
  • EBITDA 0
  • Earnings Per Share 68.22
  • Income Statements
  • Balance Sheets
  • Cash flows
Fundamental data package from $59.99 See full price
Get sample
of Fundamental API Data

Get PaxMedica, Inc. Common Stock Earnings via APIs

  • Latest Release 2024-05-13
  • EPS/Forecast -0.43

Get PaxMedica, Inc. Common Stock End-of-day Data via APIs

  • End of Day, Intraday and Live APIs
  • Splits
  • Dividends

Get PaxMedica, Inc. Common Stock latest news via APIs

T-Mobile CEO Just Sold $14 Million Worth of TMUS Stock

T-Mobile (NASDAQ:TMUS) stock is in the news Wednesday as investors react to company President and CEO Michael Sievert selling shares. According to a filing with the U.S. Securities and Exchange Commi...

PaxMedica Inc. Featured in Syndicated Broadcast Highlighting FDA Type-B Meeting to Review PAX-101 Pivotal Trial Data

LOS ANGELES, Nov. 17, 2023 (GLOBE NEWSWIRE) -- via IBN –PaxMedica, Inc. (NASDAQ: PXMD), a biopharmaceutical company focused on advancing treatments for neurological disorders, today announces that...
  • ANTI-PURINERGIC DRUG THERAPIES
  • COMPANY ANNOUNCEMENT
  • HEALTH
  • INC
  • NASDAQ:PXMD
  • NEUROLOGICAL DISORDERS
  • PAX-101
  • PAXMEDICA
  • SURAMIN
Do you have any questions?
support@eodhistoricaldata.com